StreetInsider.com News Articles

AstraZeneca's Ultomiris shows 46.6% reduction in kidney protein levels

Mon, 08 Jun 2026 03:02:10 -0400

AstraZeneca (NASDAQ: AZN) reported positive interim results from its Phase III trial evaluating Ultomiris for immunoglobulin A nephropathy, a rare kidney disease. The trial showed a statistically significant reduction in proteinuria compared to placebo.

The I CAN trial demonstrated that Ultomiris reduced 24-hour urine protein creatinine ratio by 46.6% from baseline at week 34, compared to 5.6% in patients receiving placebo. This resulted in a placebo-adjusted treatment effect of 43.4%, according to the company's statement.

The reduction in proteinuria appeared as early as week 10, with Ultomiris showing a 36.7% decrease compared to 8.5% for placebo. The effect remained sustained through 34

AstraZeneca's Ultomiris shows 46.6% reduction in kidney protein levels

Mon, 08 Jun 2026 03:02:10 -0400

The reduction in proteinuria appeared as early as week 10, with Ultomiris showing a 36.7% decrease compared to 8.5% for placebo. The effect remained sustained through 34

Ultomiris shows 43% reduction in kidney protein levels in rare disease trial

Sat, 06 Jun 2026 07:07:29 -0400

AstraZeneca's Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo in adults with immunoglobulin A nephropathy at 34 weeks in a Phase III trial, according to interim results presented at the European Renal Association Congress.

The drug showed a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline at week 34, compared to 5.6% in patients receiving placebo. The reduction was observed as early as week 10 and sustained through 34 weeks across patient subgroups.

IgAN is a rare inflammatory kidney disease that can progress to end-stage kidney disease. The condition affects the glomeruli, which filter blood in the kidneys,

AstraZeneca reports positive SERENA-6 trial results for camizestrant

Tue, 02 Jun 2026 08:02:55 -0400

AstraZeneca (NYSE: AZN) reported updated results from its Phase III SERENA-6 trial showing that camizestrant combined with a CDK4/6 inhibitor reduced the risk of disease progression or death by 55% in patients with advanced hormone receptor-positive breast cancer who developed ESR1 tumor mutations.

The trial evaluated switching to camizestrant plus a CDK4/6 inhibitor versus continuing standard treatment with an aromatase inhibitor plus a CDK4/6 inhibitor. Median progression-free survival was 16.8 months for the camizestrant combination compared with 9.2 months for the standard treatment.

For the secondary endpoint measuring durability beyond first progression, the camizestrant combination reduced the risk of second disease progression

AstraZeneca reports positive SERENA-6 trial results for camizestrant

Tue, 02 Jun 2026 08:02:55 -0400

For the secondary endpoint measuring durability beyond first progression, the camizestrant combination reduced the risk of second disease progression

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6